If 2024 was the year we discovered the “Plexin-B1 Stop Sign,” then 2026 is the year we learned how to ignore it.

As a health researcher, I’ve been tracking the shift from simple amyloid-clearing drugs (like Lecanemab) to cellular-behavior therapeutics. The goal is no longer just to dissolve plaque, but to teach the brain’s support cells—astrocytes and microglia—how to manage it properly.

Figure 1: Retraining the Brain—Clinical trials in 2026 are focusing on calming “angry” astrocytes and restoring their ability to corral toxic proteins via the Plexin-B1 pathway.

1. The SIGNAL-AD Trial: Pepinemab’s Progress

The most advanced clinical effort in the Plexin-B1 space centers on Pepinemab, a monoclonal antibody designed to block SEMA4D.

• The Mechanism: SEMA4D is the “key” that fits into the Plexin-B1 “lock.” When they connect, astrocytes “freeze up” and stop protecting neurons.
• 2026 Status: Following the Phase 2 expansion, new data suggests that by blocking this pathway, we are preserving vascular integrity. This is a major win because it significantly reduces the risk of ARIA (brain swelling), a common complication in earlier amyloid drugs.

2. The “Plaque Compaction” Breakthrough

In early 2026, research from the German Center for Neurodegenerative Diseases (DZNE) shifted the goalposts for trial success. We now know that “fluffy” amyloid plaques are more toxic than small, “dense” ones.

Trial Endpoint: New therapeutics are being measured by their ability to help astrocytes “corral” diffuse amyloid into dense, less-toxic packages. This process shields surrounding neurons from the “toxic cloud” of diffuse plaque.

3. CAR-Astrocyte Therapy: The “Super Cleaners”

The most futuristic trial of 2026 comes from Washington University in St. Louis, borrowing technology from cancer immunotherapy to create CAR-Astrocytes.

• The Innovation: These are genetically modified astrocytes equipped with a “homing device” to find amyloid-beta.
• The Result: In early human safety studies, these “super cleaners” don’t just wait for plaque to bump into them—they actively seek it out and consume it. This marks the first time we’ve successfully “reprogrammed” a brain cell to act as a precision cleaner.

The Advocate’s Perspective: Who is this for?

Based on the Molecular Subtyping we’ve tracked this year, these inflammation-targeted trials are a lifeline for patients whose blood biomarkers show:

1. Elevated GFAP: A marker for “angry” or reactive astrocytes. \(\text{Target Population: GFAP} > 200 \text{ pg/mL}\)
2. High p-tau217: Indicating active Alzheimer’s pathology. \(\text{Eligibility: p-tau217 ratio} \geq 0.06\)

If your “Alzheimer’s profile” is driven by neuroinflammation rather than just genetics, these Plexin-B1 therapies represent the most tailored approach to treatment in history.

Clinical Citations

1. ScienceDaily (2026): Scientists turn brain cells into Alzheimer’s plaque cleaners.
2. Neuroscience News: Single-Injection Immunotherapy That Halts Alzheimer’s.
3. Nature Medicine: Pepinemab and SEMA4D blockade in neurodegenerative disease.